Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A previous analysis of colorectal tumors revealed that overexpression of splice variant Rac1b occurs in around 80% of tumors with mutant BRAF and both events proved to cooperate in tumor cell survival.
|
23359345 |
2013 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
BRAF V600E is a determinant of sensitivity to proteasome inhibitors.
|
24107445 |
2013 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We investigated the clinical and molecular features of the MSH6 variants, such as the family cancer history, pathological findings, immunohistochemistry, methylation status of the MLH1 promoter and BRAF mutation in the colorectal tumor.
|
24100870 |
2013 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
|
23549875 |
2013 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
|
23251002 |
2013 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We assessed archived specimens from 732 incident colorectal tumors and characterized them as microsatellite stable (MSS), MSI high or MSI low, CIMP high or CIMP low, CIMP negative, and positive or negative for BRAF and/or KRAS mutations.
|
23665275 |
2013 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
|
23773459 |
2013 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
|
22535154 |
2012 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this study, 40 wild type KRAS and BRAF colorectal tumors were analyzed to elucidate whether PML-RARa bcr1 fusion gene may play a role in colorectal carcinogenesis.
|
22167334 |
2012 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
|
22281684 |
2012 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
|
22180495 |
2012 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
The road to resistance: EGFR mutation and cetuximab.
|
22310681 |
2012 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
However, there is a paucity of information about BRAF mutant colorectal tumors.
|
22228154 |
2012 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
|
22448344 |
2012 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.
|
20857202 |
2011 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
BRAF as a target for cancer therapy.
|
21426297 |
2011 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
|
21163703 |
2011 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
|
21716161 |
2011 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
|
21343559 |
2011 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
|
21190184 |
2011 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
|
20413299 |
2010 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
|
20350999 |
2010 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
|
21129611 |
2010 |